$6.20
0.315.26%
At Close: -
$6.29
0.091.45%
After Hours: 7:59 PM EDT
15 minutes delayed
Candel Therapeutics
CADLNASDAQ
Candel Therapeutics (NASDAQ:CADL) Stock, Analyst Ratings, Price Targets, Predictions
Candel Therapeutics Inc has a consensus price target of $11.71, established from looking at the 11 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and BMO Capital on November 13, 2023, May 22, 2023, and May 15, 2023. With an average price target of $8.33 between HC Wainwright & Co., HC Wainwright & Co., and BMO Capital, there's an implied 32.49% upside for Candel Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
BMO Capital
Credit Suisse
BMO Capital
BMO Capital
1calculated from analyst ratings
Analyst Ratings for Candel Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 11/13/2023 | Buy Now | 74.88% | HC Wainwright & Co. | Vernon Bernardino | → $11 | Reiterates | Buy → Buy | Get Alert |
| 05/22/2023 | Buy Now | 74.88% | HC Wainwright & Co. | Vernon Bernardino | → $11 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | -52.31% | BMO Capital | Evan David Seigerman | $9 → $3 | Maintains | Outperform | Get Alert |
| 03/31/2023 | Buy Now | 11.29% | Credit Suisse | Judah Frommer | $8 → $7 | Maintains | Outperform | Get Alert |
| 12/07/2022 | Buy Now | 27.19% | Credit Suisse | Judah Frommer | $10 → $8 | Maintains | Outperform | Get Alert |
| 12/02/2022 | Buy Now | 74.88% | HC Wainwright & Co. | Vernon Bernardino | → $11 | Initiates | → Buy | Get Alert |
| 03/31/2022 | Buy Now | 90.78% | BMO Capital | Evan Seigerman | $18 → $12 | Maintains | Outperform | Get Alert |
| 11/19/2021 | Buy Now | 186.17% | BMO Capital | — | — | Initiates | → Outperform | Get Alert |
| 08/23/2021 | Buy Now | 43.08% | UBS | Colin Bristow | — | Initiates | → Buy | Get Alert |
| 08/23/2021 | Buy Now | 249.76% | Jefferies | Chris Howerton | — | Initiates | → Buy | Get Alert |
| 08/23/2021 | Buy Now | 138.47% | Credit Suisse | Judah Frommer | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Candel Therapeutics (CADL) stock?
The latest price target for Candel Therapeutics (NASDAQ:CADL) was reported by HC Wainwright & Co. on November 13, 2023. The analyst firm set a price target for $11.00 expecting CADL to rise to within 12 months (a possible 74.88% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Candel Therapeutics (CADL)?
The latest analyst rating for Candel Therapeutics (NASDAQ:CADL) was provided by HC Wainwright & Co., and Candel Therapeutics reiterated their buy rating.
When was the last upgrade for Candel Therapeutics (CADL)?
There is no last upgrade for Candel Therapeutics
When was the last downgrade for Candel Therapeutics (CADL)?
There is no last downgrade for Candel Therapeutics.
When is the next analyst rating going to be posted or updated for Candel Therapeutics (CADL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Candel Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Candel Therapeutics was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
Is the Analyst Rating Candel Therapeutics (CADL) correct?
While ratings are subjective and will change, the latest Candel Therapeutics (CADL) rating was a reiterated with a price target of $0.00 to $11.00. The current price Candel Therapeutics (CADL) is trading at is $6.29, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.